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Abstract
Metformin, a biguanide drug commonly used to treat type-2 diabetes, has been noted to extend healthspan of nondiabetic
mice, but this outcome, and the molecular mechanisms that underlie it, have received relatively little experimental
attention. To develop a genetic model for study of biguanide effects on healthspan, we investigated metformin impact on
aging Caenorhabditis elegans. We found that metformin increases nematode healthspan, slowing lipofuscin accumulation,
extending median lifespan, and prolonging youthful locomotory ability in a dose-dependent manner. Genetic data suggest
that metformin acts through a mechanism similar to that operative in eating-impaired dietary restriction (DR) mutants, but
independent of the insulin signaling pathway. Energy sensor AMPK and AMPK-activating kinase LKB1, which are activated in
mammals by metformin treatment, are essential for health benefits in C. elegans, suggesting that metformin engages a
metabolic loop conserved across phyla. We also show that the conserved oxidative stress-responsive transcription factor
SKN-1/Nrf2 is essential for metformin healthspan benefits in C. elegans, a mechanistic requirement not previously described
in mammals. skn-1, which functions in nematode sensory neurons to promote DR longevity benefits and in intestines for
oxidative stress resistance lifespan benefits, must be expressed in both neurons and intestines for metformin-promoted
healthspan extension, supporting that metformin improves healthy middle-life aging by activating both DR and antioxidant
defense longevity pathways. In addition to defining molecular players operative in metformin healthspan benefits, our data
suggest that metformin may be a plausible pharmacological intervention to promote healthy human aging.
Citation: Onken B, Driscoll M (2010) Metformin Induces a Dietary Restriction–Like State and the Oxidative Stress Response to Extend C. elegans Healthspan via
AMPK, LKB1, and SKN-1. PLoS ONE 5(1): e8758. doi:10.1371/journal.pone.0008758
Editor: Anne C. Hart, Brown University, United States of America
Received May 20, 2009; Accepted November 30, 2009; Published January 18, 2010
Copyright:  2010 Onken, Driscoll. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Work was supported by National Institutes of Health funding R01AG024882, the Ellison Medical Foundation, and the National Institutes of Health
Center for Dietary Supplements Research on Botanicals and Metabolic Syndrome, grant #1-P50 AT002776-01. BO was supported by a grant from the New Jersey
Commission on Cancer Research and by a Postdoctoral Fellowship in Aging Research from the Ellison Medical Foundation/American Federation of Aging
Research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: driscoll@biology.rutgers.edu
Introduction
One of the central goals of current aging research is the
identification of chemical or genetic manipulations that lower the
incidence of age-related disease and degeneration by promoting
youthful physiology. A candidate drug for achieving this extended
healthspan is metformin, one of a class of biguanides widely used
to treat type-2 diabetes and linked to promoting a broad range of
health benefits by lowering the risks associated with the metabolic
syndrome [1]. Notably, diabetic and cardiovascular disease
patients who are prescribed metformin have increased rates of
survival [2].
There are some reports that metformin can extend healthspan
in non-disease mammals [3–5], but the nature of metformin’s
health-promoting effects is not well understood. Several lines of
evidence support that metformin may act by inducing dietary
restriction (DR) metabolism, a physiological state triggered by low
caloric intake that increases lifespan, delays age-associated
functional decline, and limits onset of age-associated disease
across species [6–13]. In mammals, both metformin-treated and
DR animals have low blood glucose and insulin levels, and glucose
uptake in muscles is increased [14–16]. In addition, both
metformin treatment and DR promote fatty acid usage in animals,
leading to lowering of fat mass [14,16,17]. That metformin
triggers DR-like effects is further supported by the finding that
gene expression patterns in metformin-treated animals are similar
to those of long-term DR mice [18].
A potential mediator of metformin benefits is the AMP-
activated kinase AMPK, which functions as a cellular energy
sensor [19–21]. Metformin activates AMPK in mammals, and
activated AMPK is required for the metformin-induced lowering
of hepatic glucose production and increased glucose uptake in
skeletal muscles [19–21]. Metformin also requires the protein-
threonine kinase LKB1, which activates AMPK, to lower blood
glucose levels [22]. Neither LKB1 nor AMPK is thought to be a
direct target of metformin, and the key upstream point of
interaction is not known. Overall, then, understanding of
molecular mechanisms of metformin action in vivo remains vague.
In particular, there is a paucity of data on the benefits of
metformin for non-diabetics and dissection of the proposed
mechanisms for metformin modulation of healthspan in genetic
models is lacking.
The nematode Caenorhabditis elegans is a powerful model system
for defining genetic and pharmacological interventions promoting
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conserved across phyla [13,23,24]. C. elegans daf mutants that alter
the formation of the long-lived dauer state via the insulin-like
signaling pathway live longer and more youthfully than wild-type
[25,26]. In this conserved signaling pathway, daf-2 encodes an
insulin/IGF-1 receptor ortholog that activates a kinase cascade
that includes the AGE-1 PI3 kinase to modulate phosphorylation
of the DAF-16/FOXO family transcription factor [25–30]. Low
signaling activity in this pathway enables the non-phosphorylated
DAF-16 to translocate to the nucleus to regulate expression of
lifespan-promoting gene batteries [28,31,32]. Another conserved
longevity pathway is dietary restriction - food limitation and
genetic mutations that impair feeding or nutrient uptake can
increase C. elegans lifespan [8,13,33–39]. Several methods of food
limitation extend lifespan independently of DAF-16 [33,35–39],
and DR further extends the already long lifespan of daf-2 mutants,
suggesting that DR increases longevity in a manner that is
independent of insulin signaling [33,39]. However, induction of C.
elegans DR by limiting the amount of bacteria on plates suggests a
lifespan-extending mechanism that is DAF-16-dependent [34],
indicating that distinct food deprivation regimens may signal
through different pathways to impact lifespan.
Pharmacological interventions that might induce healthy DR-
like metabolism are of considerable medical interest. Here we
document the effects of the putative mammalian DR mimetic
metformin on C. elegans lifespan and healthspan. We demonstrate
that metformin increases median lifespan via a mechanism that is
independent of the insulin-like signaling pathway but shares
genetic and phenotypic features of DR. Healthspan benefits of
metformin on wild type animals require the activity of the AMP-
activated kinase catalytic subunit AAK-2, its upstream kinase
LKB1/PAR-4 and, unexpectedly, transcription factor SKN-1/Nrf
expressed both in ASI neurons and intestine. Our data support
that metformin must engage both DR and oxidative stress
pathways to extend healthspan. Several aspects of metformin
action appear conserved across phyla, and thus we suggest the C.
elegans model can be exploited to identify metformin-related
biguanides that convey optimal healthspan benefit and anti-aging
effects.
Results
Metformin Treatment Extends C. elegans Median Lifespan
and Promotes Youthful Mobility Late into Adult Life
Despite the considerable potential for metformin and related
drugs to be utilized to promote healthy aging [1–5,40–42], the
molecular mechanisms by which metformin confers healthspan
benefits have not been experimentally dissected. To address this
gap in understanding, we first asked whether metformin could
induce physiological outcomes in C. elegans similar to those
reported for mammals. We monitored the survival rates of C.
elegans raised on increasing concentrations of metformin (Fig. 1A).
We found that wild-type cultures raised on 1 mM and 10 mM
metformin display survival curves that are similar to those of
control populations raised in the absence of metformin. Wild-type
animals raised on 50 mM metformin, however, show an
approximately 40% increase in median survival (21 days vs. 15
days for the mock-treated control) and exhibit a significantly right-
shifted survival curve (P,0.0001 by the Log-rank (Mantel-Cox)
test; similar results were observed in 10 out of 12 trials performed
with wild-type animals throughout the course of this study; Table
S1A). Interestingly, the effects of metformin are most pronounced
in mid-life without maximum lifespan extension, indicating that at
this concentration, metformin treatment specifically impacts
median lifespan of the culture.
As C. elegans ages, locomotion rates on solid media and in liquid
decline [43–46], and the severity of impairment is roughly
correlated with the degree of muscle deterioration that bears
striking cell biological similarity to human sarcopenia [43,47]. To
ask whether metformin can also increase quality of life by
extending locomotory healthspan, we tested the effects of 50 mM
metformin on the decline in swimming vigor (quantitated as body
bends per unit time in a liquid environment) in aging populations
(Fig. 1B). We found that early in adulthood, there is no significant
difference between the swimming rates of animals raised in the
absence of metformin and those raised on 50 mM metformin.
Thus, metformin does not induce developmental defects that
impact locomotory ability, nor does it cause hyperactive
swimming. In middle-aged 10 day-old animals, however, animals
raised on 50 mM metformin display significantly higher swimming
rates as compared to the non-treated control group. By day 15 of
life, swimming rates decline further in both groups, and, although
the difference in the average number of body bends between the
two groups is not as great as on day 10, the metformin-treated
animals are still significantly better swimmers late into adulthood.
Thus, metformin extends locomotory healthspan, with the greatest
impact exhibited in mid-life. Taken together, results in Fig. 1A and
1B demonstrate that metformin extends mid-life viability and
slows locomotory decline, supporting that metformin promotes
and/or extends youthful physiology in C. elegans.
Metformin Extends Median Lifespan Independently of
the Insulin Signaling Pathway
Downregulation of the insulin signaling pathway increases
C. elegans lifespan and locomotory healthspan in a FOXO/DAF-
16-dependent manner [25,26,44,48]. To investigate whether
metformin extends median lifespan by acting through the insulin
signaling pathway, we tested a daf-16 null mutant strain that lacks
the FOXO transcription factor needed for the longevity effects of
the insulin signaling pathway (Fig. 1C). We found that, like wild-
type, daf-16(mgDf50) mutants raised on 50 mM metformin (but not
on 1 or 10 mM metformin) display a median lifespan extension
(11 days for the daf-16 deletion mutant vs. 15 days with metformin
treatment (P=0.0111 by the Log-rank test), an approximately
36% increase with metformin; see Table S1B for details on these
data and similar results from three other trials). We conclude that
metformin can extend median lifespan via a mechanism that is
independent of DAF-16/FOXO, consistent with the conclusion
that metformin exerts healthspan benefits via a mechanism distinct
from the insulin-like signaling pathway.
To further address requirements for insulin signaling in
metformin action, we tested for metformin effects on the lifespans
of insulin signaling pathway mutants. We raised long-lived age-
1(hx546) mutants deficient in PI-3 kinase signaling in the absence
or presence of metformin (Fig. 1D). We found that 50 mM
metformin treatment extends median lifespan in the age-1 mutant
(30 days with metformin treatment vs. 21 days for the age-1 control
(P=0.0014 by the Log-rank test), an approximate 43% increase).
Similar to treated wild-type and daf-16(mgDf50) animals, the age-1
median lifespan, but not the maximum lifespan, is increased by
metformin treatment. We observed similar results to those
depicted in Fig. 1D in a repeat trial using age-1(hx546) animals
and the same trend in a trial using the long-lived daf-2(e1370)
mutant strain (Table S1C). That metformin effects on lifespan are
additive with low insulin signaling mutants suggests that
metformin might act primarily in a pathway parallel to that of
insulin signaling to confer health benefits.
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in the Eat-2 DR Model, Suggesting Healthspan Benefits
May Be Conferred via a DR Pathway
Having ruled out that metformin confers major healthspan
benefits via the insulin signaling pathway, we considered the
possibility that metformin increases median lifespan by triggering
DR-like physiology, a plausible hypothesis given suggestions that
metformin acts as a DR mimetic in mammals [4,5,18]. We
predicted that if metformin triggers a DR-like metabolic state,
drug treatment would not greatly increase median lifespan of
animals already undergoing DR. To address this hypothesis, we
tested the effects of metformin treatment on eat-2(ad1116),al o n g -
lived strain that is defective in pharyngeal pumping and is
considered DR-constitutive due to its impaired ability to feed [33]
(Fig. 2A). We were unable to identify any concentration of
metformin that could extend median lifespan in the eat-2
background. Notably, in two out of four trials, doses of metformin
that are effective in increasing median lifespan in other tested
strains were actually detrimental to the viability of eat-2 mutants
(Fig. 2A and Table S1D). In the trial shown in Fig. 2A, metformin
at 10 mM and 50 mM decreases eat-2 median lifespan (19 days
for both 10 mM and 50 mM in eat-2 vs. 23 days for the control;
P=0.0050 and P=0.0033, respectively, by the Log-rank test).
That metformin does not further increase median lifespan in a
DR-constitutive genetic background suggests that metformin acts
through a DR mechanism. Additionally, because high doses of
metformin can result in reduced lifespan in eat-2 mutants, it
appears that when an animal is already in the DR state, further
stimulation of DR physiology by metformin leads to diminishing,
even harmful, effects, a phenomenon typical of extreme calorie
Figure 1. Metformin increases healthspan without a requirement for function of the insulin signaling pathway. A. Survival curves of
wild-type (N2) animals raised at 20uC on nematode growth media plates containing either no metformin or final concentrations of 1 mM, 10 mM, or
50 mM metformin. (Note that C. elegans has a highly protective cuticle and intestinal lining that generally limit drug uptake such that it is not unusual
for polar drugs to be applied at a concentration 1000 fold higher than their predicted affinity for the target [94,95]; physiological levels of drug in the
animals are anticipated to be much lower). For the trial presented here, median survival for animals on 0 mM, 1 mM, 10 mM, and 50 mM metformin
plates was 15, 15, 17, and 21 days, respectively. The survival curves of the nematodes raised on 0 mM, 1 mM, and 10 mM metformin plates are not
significantly different, while the survival curve for animals raised on 50 mM metformin is significantly different than the 0 mM metformin control
(P,0.0001 by the Log-rank (Mantel-Cox) test; benefits are lost at 100 mM metformin, data not shown). The pooled data for all trials show an
approximately 27% increase in median lifespan with 50 mM metformin treatment and a significantly right-shifted survival curve (P,0.0001 by the
Log-rank test), see Table S1A. All studies documented here involved life-long metformin exposure, but a preliminary trial in which metformin was
introduced at the last larval stage suggests that treatment in adult life is sufficient to confer some lifespan benefit (data not shown). B. Swimming
rates for wild-type animals raised from eggs on plates (time 0) containing either no metformin or 50 mM metformin at 20uC. We recorded the
number of body bends/30 seconds for individual animals placed in liquid media at early adulthood (5 days), mid-life (10 days), and late life (15 days).
We present the averages of three independent trials. Metformin-treated animals swim at similar rates in young adulthood, supporting that metformin
does not induce hyperactive swimming or confer developmental defects, but the swimming rates of animals raised on 50 mM metformin are
significantly higher than those of the control group on days 10 and 15 (P=0.0058 and P=0.0346, respectively, by unpaired t tests), indicating
extended mid-life and late-life locomotory ability consequent to metformin treatment. C. Survival curves of null mutant daf-16(mgDf50) raised on
0 mM and 50 mM metformin plates at 20uC. The median survival is 11 and 15 days for animals raised on 0 mM and 50 mM metformin, respectively,
and the survival curves of the two groups are significantly different (P=0.0111 by the Log-rank test). 1 mM and 10 mM metformin do not significantly
change the survival curves of daf-16(mgDf50) animals (data not shown). We performed this experiment a total of four times with similar results
(pooled data show a 15% median lifespan increase and a significantly right-shifted survival curve (P,0.0001, Log-rank) for animals treated with
50 mM metformin, see Table S1B for additional data). D. Survival curves of age-1(hx546) mutants raised on 0 mM and 50 mM metformin plates at
20uC. Median survival for animals on 0 mM and 50 mM metformin is 24 and 31 days, respectively, and the survival curves are significantly different by
the Log-rank test (P=0.0014). We found similar median survival extension in a single repeat of this experiment (pooled data for the two trials show an
approximate 36% median lifespan increase and significantly different survival curves (P,0.0001, Log-rank), see Table S1C).
doi:10.1371/journal.pone.0008758.g001
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triggers several DR phenotypes in wild-type C. elegans without impairing feeding. A. Survival curves of eat-2(ad1116) mutants raised on
0 mM, 1 mM, 10 mM, and 50 mM metformin plates at 20uC. The median survival is 23, 25, 19, and 19 days for 0 mM, 1 mM, 10 mM, and 50 mM
metformin, respectively. The survival curves of the animals raised on 0 mM and 1 mM metformin are not significantly different, but survival of the
10 mM and 50 mM groups are significantly reduced compared to controls (P=0.0050 and 0.0033, respectively, by the Log-rank test). We performed
this experiment a total of four times, with two of the trials showing significantly different survival curves for the 10 mM and 50 mM groups. Pooled
data show approximately 9% declines in median lifespan for 10 mM and 50 mM metformin treatment and significant shifts in survival curves
(P=0.0037 and 0.0114 for 10 mM and 50 mM metformin treatment, respectively, by the Log-rank test), see Table S1D. B. Age pigment fluorescence
measurements in wild-type animals raised on 0 mM, 1 mM, 10 mM, and 50 mM metformin plates. We found that age pigment fluorescence
decreases with increasing metformin concentration with the levels in the 50 mM group significantly lower than the controls (P=0.0270 by an
unpaired t test). Scores are the average age pigment fluorescence intensity levels of three independent trials. We also observed shifts in the excitation
wavelength corresponding to peak age pigment fluorescence intensity in animals treated with 100 mM metformin (see Fig. S1). C. Progeny profiles
of wild-type animals raised on 0 mM, 1 mM, 10 mM, and 50 mM metformin. We recorded the number of progeny produced by 60 individuals for
each group for each day of egg-laying. We found no significant differences between the progeny profiles of the 0 mM, 1 mM, and 10 mM metformin
groups. The 50 mM metformin-treated animals, however, exhibit delays in egg-laying, with significantly higher percentages of total progeny
produced on days 3 and 4 compared to the controls (P=0.0431 and 0.0084 for days 3 and 4, respectively, by an unpaired t test). The 50 mM group
also shows lower levels of progeny production on days 1 and 2 compared to controls, with the levels on day 2 being significantly different (P=0.0361
by an unpaired t test). Data shown represent the average of three independent trials. D. Quantitation of Nile Red staining of lipid deposits in wild-
type animals raised on 0 mM, 1 mM, 10 mM, and 50 mM metformin. Fluorescence levels decrease with increasing metformin concentration, with
significantly lower levels in the 10 mM and 50 mM metformin groups (P=0.0400 and 0.0205 for 10 mM and 50 mM metformin, respectively, by an
unpaired t test). Data represent the average of three independent experiments. Animals not stained with the Nile Red dye produced no detectable
levels of fluorescence in this wavelength range (data not shown). E. Pharyngeal pumping rates of wild-type animals raised on 0 mM, 1 mM, 10 mM,
and 50 mM metformin. We recorded pumping rates of 30 individuals for 30 seconds on day 4 of life, and the averages of three separate experiments
are shown. Pharyngeal pumping did not differ significantly for any of the groups (P=0.9231, 0.1689, and 0.9142 for 1 mM, 10 mM, and 50 mM
metformin, respectively, by unpaired t tests).
doi:10.1371/journal.pone.0008758.g002
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[49].
Metformin Treatment Induces DR-Associated Features in
C. elegans
Given the genetic indication that metformin extends median
lifespan via a DR mechanism, we examined metformin-treated
animals for other features characteristic of DR animals. In C.
elegans, DR is linked to a distinctive fluorescent age pigment profile,
contributed by advanced glycation end products and lipofuscin,
that accumulate in intestinal lysosomes [50]. Animals in the DR
state have low levels of age pigment fluorescence, and they display
a DR-specific shift in the excitation maximum for peak age
pigment fluorescence early in life. We therefore measured age
pigments in wild-type animals raised on metformin in order to
see if the drug could trigger the DR-associated age pigment
fluorescence profile. As shown in Fig. 2B, age pigment levels
decrease with increasing levels of metformin treatment, with
50 mM metformin significantly lowering age pigment fluorescence
levels. We also noted the shift in age pigment excitation maximum
wavelengths at high metformin concentrations (Fig. S1). Thus,
metformin treatment induces age pigment features that uniquely
characterize the DR state.
Another characteristic of DR C. elegans is an extended period of
egg-laying with an overall reduction in progeny production as
compared to well-fed animals [51]. In order to examine whether
metformin affects C. elegans reproduction, we measured egg-laying
and progeny production of metformin-treated animals (Fig. 2C).
We found that 50 mM metformin extends the number of days that
wild-type hermaphrodites lay eggs, resulting in approximately one
extra day of egg-laying. In addition, in the early period of egg-
laying, the relative number of progeny produced per day is
decreased in metformin-treated animals. Thus, metformin impacts
reproduction in a manner typical of DR.
Feeding-defective strains undergoing DR tend to be smaller
than well-fed worms and have decreased levels of fat deposits [52].
We examined overall fat levels in wild-type animals raised in the
presence or absence of metformin using Nile Red, a fluorescent
vital stain that has been used to measure lipid deposits [53,54]. We
quantitated Nile Red fluorescence in vivo using a spectrofluorimeter
and methods similar to those used to measure age pigment levels
(age pigments are measured at excitation wavelengths between
280–410 nm and an emission wavelength of 430 nm, while Nile
Red fluorescence is measured at an emission wavelength of
658 nm and an excitation wavelength of 578 nm, so measure-
ments of age pigments and fat can be made independently,
without cross-interference). As shown in Fig. 2D, animals raised in
the presence of 10 mM and 50 mM metformin exhibit lower levels
of Nile Red fluorescence as compared to controls. Thus, like C.
elegans under DR, metformin decreases levels of stored fat.
Metformin Does Not Directly Impact Feeding Proficiency
One trivial mechanism by which metformin could trigger DR in
C. elegans could involve lowering the pharyngeal pumping rate,
which could induce DR by limiting feeding (akin to what is
thought to occur in eat-2 animals). To rule out this possibility, we
measured pharyngeal pumping in wild-type animals raised in
the presence of metformin (Fig. 2E). We found no significant
differences in pharyngeal pumping in animals treated with
metformin compared to non-treated controls, indicating that
metformin is unlikely to directly limit feeding capacity.
Overall, our genetic data support that healthspan benefits of
metformin are induced via DR rather than insulin signaling
pathways. We find that metformin triggers multiple indicators of
DR (increased median lifespan, extended locomotory healthspan,
delayed egg-laying, lowered progeny production, lowered age
pigment levels, and decreased fat) in a dose-dependent manner.
These data support the hypothesis that metformin activates DR
physiology in well-fed C. elegans, and, given mammalian data
indicating that metformin induces features of DR [14–18], suggest
that metformin acts via a conserved metabolic mechanism to
extend healthspan.
Metformin-Induced Extended Median Lifespan Requires
AMPK
We next took genetic approaches toward identifying molecules
that mediate metformin healthspan benefits in physiological
context. In mammals, energy sensor AMPK is activated by
metformin [20,21], and metformin-activated AMPK increases
glucose uptake in muscle and inhibits gluconeogenesis in
hepatocytes [19]. C. elegans aak-2 encodes one of two homologs
of the catalytic a subunit of the AMPK heterotrimeric complex,
and nematode AAK-2 is activated by AMP, as occurs for
mammalian AMPK [55]. Overexpression of the catalytic AMPK
a subunit AAK-2 increases C. elegans longevity [55], and aak-2 is
required for the increased lifespan of several longevity mutants
[56] and for lifespan extension under at least one tested mode
of DR induction [34]. To investigate the role of AMPK in
metformin-induced extended median lifespan in C. elegans,w e
tested for metformin effects in the backgrounds of two indepen-
dent aak-2 alleles: aak-2(ok524), a presumed molecular null [55],
and aak-2(rr48), which carries a point mutation predicted to
disrupt the catalytic activity of the a subunit [57]. As shown in
Fig. 3A, no tested metformin concentration significantly increased
the median lifespan of either aak-2 mutant (in three repeated trials
for each strain; Table S1E). Instead, metformin treatment
decreased mid-life viability in aak-2 mutants in a dose-dependent
manner (Table S1E) and reduced locomotory ability in both aak-2
strains (Fig. S2A). We conclude that the catalytic AMPK subunit is
required for median lifespan extension and locomotory healthspan
increase in metformin-treated C. elegans. Moreover, we note that in
the absence of healthspan-promoting AMPK activity, metformin
confers deleterious consequences on culture survival and swim-
ming prowess. Interestingly, although we did not note statistically
significant differences in Nile Red staining (Fig. S2B), we did find
lower age pigments in aak-2(ok524) mutants treated with 50 mM
metformin vs. controls (Fig. S2C, other allele not tested). This
observation suggests age pigment changes might be conferred via
an AMPK-independent mechanism.
Kinase LKB1 Is Required for Metformin Healthspan
Benefits
AMP is known to activate AMPKvia two mechanisms. First, AMP
binds allosterically to activate AMPK ,5-fold [58]. Second, and
likely more importantly, AMP binding promotes AMPK a subunit
phosphorylation by the LKB1 kinase [59–63] to confer ,100x
activation [64]. In LKB1 kinase-deficient murine cells, AMPK is not
activated by phenformin, a metformin-related biguanide [65],
supporting an essential role for LKB1 kinase in drug action. We
therefore tested whether C. elegans LKB1 homolog PAR-4 is required
for healthspan benefits of metformin in the nematode model. We
treated two independent lkb1/par-4 temperature-sensitive mutants
[66,67] with increasing metformin concentrations and monitored
viability during adulthood. Metformin treatment did not confer
healthspan benefits in the lkb1/par-4 mutants (Fig. 3B; see Table S1F
for data from three trials using the par-4(it47) strain and four trials
with par-4(it57) animals). Interestingly, as we found to be the case
Metformin Extends Healthspan
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detrimental when LKB1 is disrupted (Table S1F). We conclude that
lkb1/par-4 is required for health-promoting action of metformin in C.
elegans and, based on previous studies in C. elegans [68] and mammals
[59–61] identifying LKB1 as the activating kinase of AMPK, suggest
that LKB1 acts upstream of AAK-2 to transduce metformin
healthspan benefits.
Metformin Requires the SKN-1 Transcription Factor to
Extend Median Lifespan
How metformin-activated AMPK exerts downstream effects to
confer healthspan benefit is not known. Given our evidence that
metformin induces DR-like physiology in C. elegans (Fig. 2B–E; Fig.
S1), we sought to evaluate how AMPK activation and dietary
restriction metabolism might be linked by testing known DR
modulators. The C. elegans SKN-1 transcription factor, functionally
and structurally related to mammalian Nrf transcription factors,
contributes to lifespan extension via both DR and oxidative stress
response pathways [35,69,70]. To investigate whether SKN-1 is
required for metformin to increase median lifespan, we tested for
metformin effects on the skn-1(zu135) mutant, which encodes
truncated SKN-1 isoforms lacking DNA binding domains [35,70].
We find that metformin no longer confers median lifespan benefit
in the skn-1(zu135) background (Fig. 4A; similar results in a repeat
of this experiment in Table S1G), suggesting that skn-1 plays an
essential role in metformin’s positive effects.
As independent confirmation that metformin promotes SKN-1
activation, we tested for SKN-1::GFP nuclear translocation in
intestine in response to metformin. SKN-1::GFP accumulates in
intestinal nuclei under conditions of oxidative stress or low insulin
signaling [35,69,71]. Consistent with metformin activation of
intestinal SKN-1 to increase healthspan, we found that metformin
treatment results in an increase in the frequency of nuclear SKN-
Figure 3. Metformin extends median lifespan via an AMPK and LKB1-dependent mechanism. A. Survival curves of AMPK catalytic
subunit mutants aak-2(ok524) and aak-2(rr48) raised on metformin plates at 20uC for their entire lives. Median survival for aak-2(ok524) animals on
0 mM, 1 mM, 10 mM, and 50 mM metformin is 17, 17, 15, and 15 days, respectively, and there are no significant differences between any of the
survival curves (Log-rank test). Median survival for aak-2(rr48) animals on 0 mM, 1 mM, 10 mM, and 50 mM is 13, 15, 15, and 15 days, respectively,
and there are no significant differences between the survival curves. Pooled data from three independent trials for each aak-2 strain show
approximately 11% declines with 10 mM and 50 mM metformin treatment in aak-2(ok524) animals, and approximately 6% and 19% declines with
10 mM and 50 mM metformin treatment, respectively, in aak-2(rr48) animals. Survival curves are significantly shifted to the left in aak-2(ok524)
animals treated with 10 mM and 50 mM metformin (P=0.0209 and ,0.0001, respectively), and in aak-2(rr48) animals raised on 10 mM and 50 mM
metformin (P=0.0442 and 0.0004, respectively). See Table S1E for additional data. We conclude that AMPK activity is needed for median lifespan
extension induced by metformin, and that metformin has detrimental lifespan effects in the absence of AMPK. B. Survival curves of temperature-
sensitive lkb-1/par-4 mutants grown on 0 mM and 50 mM metformin plates, maintained at 15uC and shifted to 25uC at the L4 stage. C. elegans par-4
encodes an ortholog of mammalian LKB1, which has been shown to activate AMPK in both mammals and nematodes. Median survival is 9 days for
the par-4(it47) mutants grown on both 0 mM and 50 mM metformin, and there is no significant difference between the survival curves by the Log-
rank test. Similarly, par-4(it57) animals grown on both 0 mM and 50 mM metformin have a median survival of 11 days, and their survival curves are
not significantly different by the Log-rank test. Pooled data from three independent trials using the par-4(it47) strain show no differences in median
lifespan for 0 mM vs. 50 mM metformin-treated animals (9 days for both conditions), although the 50 mM metformin survival curve is significantly
shifted to the left (P=0.0500, Log-rank; Table S1F). Pooled data for four independent trials with the par-4(it57) mutants show a decrease in median
lifespan (9 days for 50 mM metformin plates vs. 10 days for 0 mM metformin; Table S1F) and a significantly left-shifted survival curve for 50 mM
metformin-treated animals (P=0.0063, Log-rank; Table S1F). Thus, LKB1 is required for metformin to increase median lifespan, and, as is seen in the
absence of AMPK, metformin has harmful effects when LKB1 is disrupted.
doi:10.1371/journal.pone.0008758.g003
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PLoS ONE | www.plosone.org 6 January 2010 | Volume 5 | Issue 1 | e8758Figure 4. Metformin requires transcription factor SKN-1 to increase median lifespan, via a mechanism that acts in both ASI neurons
and the intestine. A. Survival curves of skn-1(zu135) mutants raised on 0 mM and 50 mM metformin plates at 20uC. The median survival of animals
raised on both 0 mM and 50 mM metformin plates is 9 days, and the survival curves are not significantly different. Pooled data from a total of two
experiments show no change in median lifespan or survival curves (see Table S1G). We conclude that skn-1 is required for metformin’s effect on
median lifespan. B. SKN-1 localization in L4-stage wild-type animals expressing SKN-1::GFP grown on 0 mM and 50 mM metformin plates at 20uC.
SKN-1 is present constitutively in the nuclei of ASI neurons [69] where it mediates the increased longevity response under dietary restriction. Under
oxidative stress and with reduced insulin signaling, SKN-1 accumulates in intestinal nuclei leading to SKN-1 target gene expression [35,69,71].
Whereas SKN-1::GFP is not apparent in intestinal nuclei of animals raised on 0 mM metformin plates (top panel), SKN-1::GFP accumulates in intestinal
nuclei (arrowheads, bottom panel) of animals exposed to 50 mM metformin. C. Survival curves of skn-1(zu135) animals expressing skn-1 isoforms
from either the native skn-1 promoter (Is007[skn-1::gfp]), an ASI neuron-specific promoter (geIs9[gpa4p::skn-1b::gfp]), or an intestine-specific promoter
(geIs10[ges-1p::skn-1c::gfp]), and raised on 0 mM or 50 mM metformin plates at 20uC. While expressing skn-1::gfp from the native skn-1 promoter
rescues the inability of metformin to increase the lifespan of skn-1(zu135) mutants (see A) (median lifespan of skn-1(zu135); Is007[skn-1::gfp] animals
raised on 0 mM or 50 mM metformin is 13 and 20 days, respectively, and metformin treatment shifts the survival curve or these animals significantly
to the right, P=0.0008 by the Log-rank test), expressing skn-1 only in the ASI neurons or only in the intestine does not. In fact, metformin has
significantly detrimental effects in skn-1(zu135) mutants that express skn-1::gfp only in the ASI neurons (mean lifespan for these animals raised on
0 mM or 50 mM metformin is 18 and 13 days, respectively, and the surivival curve with metformin treatment is shifted significantly to the left,
P,0.0001 by the Log-rank test). We performed each of these lifespan assays a total of three times with similar results, see Table S1G. Pooled data for
skn-1(zu135) animals expressing skn-1::gfp from the native skn-1 promoter show a median lifespan increase from 16 days for animals on 0 mM
metformin to 20 days for animals on 50 mM metformin (a 25% increase), with a significantly right-shifted survival curve (P,0.0001 by the Log-rank
test, Table S1G). Pooled data for skn-1(zu135) mutants expressing skn-1::gfp only in the ASI neurons show a median lifespan decrease from 16 days for
animals on 0 mM metformin to 13 days for animals on 50 mM metformin, with a significantly left-shifted survival curve (P,0.0001 by the Log-rank
test, Table S1G). Note that in these experiments we cannot rule out that the tissue-specific expression of skn-1 driven by heterologous promoters
provides the normally appropriate level of expression, and thus the negative effects in ASI and intestine must be evaluated with cautious attention to
this caveat. D. Quantification of SKN-1::GFP nuclear localization. Wild-type animals expressing SKN-1::GFP display significantly higher incidences of
SKN-1::GFP accumulation in intestinal nuclei vs. controls when exposed to 50 mM metformin (P,0.0001 by the Chi-square test). Strikingly, AMPK is
required for this effect: 50 mM metformin does not induce nuclear SKN-1::GFP accumulation in the aak-2(ok524) mutant background. ‘‘Low’’ indicates
very little or no SKN-1::GFP localization to intestinal nuclei; ‘‘Medium’’ indicates strong SKN-1::GFP localization to nuclei in the anterior and/or
posterior of the intestine; ‘‘High’’ indicates strong SKN-1::GFP accumulation in nuclei throughout the intestine. Although 10 mM NaN3 did not trigger
SKN-1::GFP nuclear localization on its own, we note that NaN3 is an oxidative stressor that has been shown to induce nuclear SKN-1::GFP
accumulation at high concentrations [96]. To confirm that 50 mM metformin can induce SKN-1::GFP nuclear accumulation in the absence of NaN3,w e
performed these experiments with N2 Is007[skn-1::gfp;rol-6dm] animals raised from eggs on 0 mM and 50 mM metformin and observed in liquid M9
media. We again found that 50 mM metformin significantly increases SKN-1::GFP nuclear accumulation under these conditions (Fig. S3A).
doi:10.1371/journal.pone.0008758.g004
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constitutively to the nuclei of the ASI neurons so similar study in
these neurons is not possible [69]). We also found that metformin
treatment induces the expression of SKN-1 target gst-4, which
encodes glutathione transferase-4 and is involved in the oxidative
stress response in the intestine (Fig. S3B) [72,73]. We conclude that
metformin stimulates SKN-1 nuclear translocation in the intestine
to promote SKN-1-dependent transcription. Our data reveal SKN-
1 as a critical executor of metformin-induced healthspan extension
in C. elegans. To the best of our knowledge,this is thefirstimplication
of SKN-1 in metformin-mediated benefits. Our data raise the
possibility that mammalian Nrf transcription factors may play
similar roles.
Metformin Must Activate Both SKN-1-Dependent
Pathways of DR Activation and Oxidative Stress
Resistance to Extend C. Elegans Healthspan
skn-1 is expressed in ASI neurons and intestine but appears to
affect different pathways in these cell types to influence either DR
or oxidative stress resistance lifespan extension [35,69,71]. skn-1
expressed in only two ASI neurons in an otherwise skn-1 mutant
background can promote the long lifespan under dietary
restriction, whereas skn-1 expressed in the intestine contributes
oxidative stress resistance and the increased longevity resulting
from reduced insulin signaling [35,69,71].
To determine whether SKN-1 acts in either the ASI neurons or
the intestine to mediate metformin-induced healthspan extension,
we tested genetic mosaics that express tissue-appropriate isoforms
of skn-1 from the gpa-4 promoter specific to ASI neurons [74] or
the ges-1 promoter specific to the intestine [75] in the skn-1(zu135)
background (Fig. 4C). We find that metformin does not increase
the healthspan of skn-1(zu135) mutants that express skn-1 in only
the ASI neurons or that express skn-1 only in the intestine.
However, we find that metformin does significantly increase the
median lifespan of skn-1(zu135) mutants expressing skn-1 from its
native promoter, i.e., in both the ASI neurons and the intestine (20
days for 50 mM metformin treatment vs. 13 days for the control, a
54% increase; P=0.0008 by the Log-rank test). We observed
similar results in two additional trials of each of these experiments
(Table S1G).
Taken together, our results suggest that SKN-1 must function in
both the ASI neurons and the intestine for metformin to convey
healthspan benefits in C. elegans.
AMPK Acts Upstream to Activate SKN-1 Transcriptional
Activity
Given that metformin effects require both AMPK and SKN-1,
we wondered whether they act sequentially in the same pathway.
To begin to evaluate their relative order of action we tested
whether the nuclear localization of SKN-1::GFP depends on
AMPK activity by constructing SKN-1::GFP reporter lines that
included aak-2(ok524) and monitoring GFP localization with and
without 50 mM metformin. We found that metformin-induced
SKN-1::GFP nuclear localization is strongly AMPK-dependent: in
the aak-2(ok524) mutant background, metformin treatment no
longer induces nuclear SKN-1::GFP accumulation (Fig. 4D).
These data suggest that AMPK acts upstream of SKN-1 to
transduce metformin’s effects, at least in intestine.
We suggest a model in which metformin activates both DR
metabolism (presumably through two ASI neurons), as well as
oxidative stress resistance mechanisms—this combination confers
metformin-dependent healthspan extension (Fig. 5).
Discussion
Here we describe the first genetic dissection of molecular
requirements for metformin-induced healthspan extension in a
whole animal context. We report that metformin extends C. elegans
median lifespan via a mechanism that requires the cellular energy
sensor AMPK, its upstream activating kinase LKB1, and the
downstream DR/oxidative stress responsive transcription factor
SKN-1, but is independent of the insulin signaling pathway
components that modulate longevity. Our data on metformin
outcomes are consistent with the interpretation that metformin
acts, at least in part, as a dietary restriction mimetic in C. elegans
and suggest that this activity is executed via a mechanism that is
conserved from nematodes to humans. Implications of these
findings could influence development of plausible anti-aging
therapies based on a drug currently used in the clinic.
Metformin Prolongs Youthfulness and Extends the
period of Healthy Maintenance in C. elegans Cultures via
a Mechanism That Induces DR Characteristics
In mammals, biochemical and physiological studies have
suggested that metformin acts as a DR mimetic [2,4,5,18], but
until recently [18] genetic data in support of this activity have been
lacking. Our results support that metformin induces a DR-like
Figure 5. Summary model of metformin action on C. elegans healthspan. Metformin activates SKN-1 to trigger DR-like metabolism and
intestinal anti-oxidant gene expression. SKN-1 is needed in both the two ASI neurons and in the intestine for metformin to be beneficial. Since SKN-1
in the ASI neurons has been shown previously to be needed for DR lifespan extension [35], it seems probable that the ASIs play a role in the DR-like
metabolism induced by metformin. LKB1 and AMPK are needed for metformin health benefits and AMPK acts upstream of intestinal SKN-1 for
metformin benefits. *The relative order of action of SKN- and AMPK has not yet been experimentally addressed for ASI neurons. Dotted line—it is
possible that signaling in the neurons could activate SKN-1 in intestine.
doi:10.1371/journal.pone.0008758.g005
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pumping function required for feeding, but it does induce multiple
features of DR: 1) extension of median lifespan; 2) DR-specific
age pigment properties [50]; 3) low fat stores; and 4) reduced
fecundity. Furthermore, metformin is unable to extend median
lifespan of the feeding-compromised eat-2 mutant; instead,
metformin doses that normally benefit wild-type actually are
deleterious to eat-2, possibly by inducing a starvation-like state
from excessive metabolic shutdown. Both of these responses are
consistent with metformin inducing a DR-like state that is
exacerbated in the eat-2 mutant. Finally, we show that metformin
requires at least one essential DR transcription factor, SKN-1 [35],
to confer healthspan benefit. Taken together, our data strongly
support that metformin acts in C. elegans at least in part by shifting
metabolism to a DR-like state and, importantly, suggest that
the capacity for metformin to do so has been maintained from
invertebrates to humans.
One seemingly paradoxical observation in relation to classic DR
outcomes is that we did not find that maximum lifespan is
extended by metformin treatment as is typical of DR across species
[6–13]. One possible reason for this is that the 50 mM treatment
that we selected for most analyses might actually be suboptimal for
healthspan benefits, corresponding to a dose that shifts animals
partially into a zone of metabolism in which starvation con-
sequences begin to negatively impact viability over the longterm.
Alternatively, increased ROS burden associated with metformin
treatment might not be effectively managed later in life (see further
discussion below). Known side effects of biguanides in humans
include deleterious lactic acidosis in treated diabetics [76], and
thus it is also possible that acidosis limits healthspan benefits.
AMPK And LKB1 Are Required for Metformin to Positively
Impact Healthspan
In mammalian models, metformin and other biguanides activate
AMPK in reactions needed for some metformin-associated
outcomes [20,21,65]. In C. elegans, both an aak-2 deletion mutant
and a catalytically inactive aak-2 mutant are defective in metformin-
induced median lifespan extension. Requirement for AMPK
activity for healthspan benefits may be a feature of metformin
action conserved across species.
AMPK has been implicated in C. elegans lifespan regulation in
multiple pathways [55,56,77], including DR [34] and the lifespan-
promoting activities of limiting glycolytic flux by 2-deoxyglucose
treatment [78], which features some aspects of DR. Interestingly,
however, the requirement for AMPK in C. elegans DR appears
dependent upon the approach to food limitation–extending
lifespan by directly inducing DR through bacterial dilution on
plates requires AMPK activity in C. elegans [34] but aak-2 has been
reported to be dispensable for the long lifespan of DR-constitutive
eat-2 animals [56]. Different DR models in C. elegans may thus have
distinct genetic requirements, and multiple DR pathways that
extend lifespan may co-exist. Indeed, our observation that
functional aak-2 is required for metformin to reduce overall fat
levels, but not age pigment accumulation (Fig. S2B and Fig.S2C),
suggests that metformin may be signaling through different
pathways to trigger DR-like physiology.
How is AMPK likely to promote DR-like metabolism? In
mammals, there are several known AMPK targets that modulate
metabolic pathways including those responsible for fatty acid,
protein, and cholesterol synthesis, as well as those that mediate
glucose transport and glycolysis in liver and muscle [77,79,80].
The power of the worm model is that C. elegans proteins
orthologous to mammalian metformin targets like glycogen
synthase (which is inhibited in mammals by AMPK [81,82]),
TOR kinase complex TORC2 (inhibited by AMPK from
promoting gluconeogenesis by inducing PEPCK and glucose-6-
phosphatase transcription [83]), PFK-2/FBPase-2 (a target of
AMPK that regulates glycolytic/gluconeogenic flux [84]), and
hormone-sensitive lipase (LIPE) (which mobilizes free fatty acids
from stored triglycerides [85]) can be manipulated to test relative
roles in the various measures of healthspan.
In terms of upstream activation of AMPK, we report that kinase
LKB1 is also essential for metformin benefit. Given that LKB1 is
the identified upstream kinase for aak-2 [68], the simplest model is
that metformin promotes activation of LKB1, which phosphory-
lates and activates AMPK to promote healthspan. That this
activation pathway appears operative in mammalian DR and
metformin action [19–21] is further evidence for metformin acting
via a mechanism conserved from nematodes to humans. Exactly
how LKB1 is activated by metformin is a question that remains to
be addressed.
Metformin Requires the Functionally Conserved SKN-1
Transcription Factor in Both the ASI Neurons and the
Intestine to Increase Healthspan
C. elegans SKN-1 is needed for endodermal development,
controls the phase 2 detoxification response that defends against
oxidative stress, and is required for the oxidative stress resistance
and longevity phenotypes associated with reduced insulin signaling
[69–71]. SKN-1 also functions in two ASI neurons to promote
lifespan extension under DR conditions [35]. Here we report for
the first time that SKN-1 is required for metformin to extend
median lifespan in C. elegans, and provide evidence that metformin
activates both DR and oxidative stress resistance mechanisms to
promote healthspan.
The requirement for SKN-1 activity in only ASI neurons for
DR benefits [35] suggests that ASI normally senses food limitation
and signals to coordinate metabolism in the rest of the body
tissues. That metformin induces a DR-like state via a SKN-1-
dependent mechanism raises the possibility that critical metformin
action in DR induction might be similarly targeted to these two
regulatory neurons in C. elegans. Indeed, we find that SKN-1 action
in ASI neurons is necessary for the healthspan benefits of
metformin, although SKN-1 function in the ASI neurons is not
sufficient for metformin-mediated healthspan extension.
SKN-1 also acts in the C. elegans intestine to promote longevity
in response to low insulin pathway signaling and oxidative stress
conditions [35,69,71]. We have shown that metformin activates
AMPK to promote SKN-1 nuclear translocation and expression of
SKN-1 target gst-4 in intestine. Intestinal SKN-1 activity is
necessary but not sufficient for metformin healthspan benefits.
Because we observed healthspan benefits only under conditions in
which skn-1 is expressed from its native promoter (characterized to
be active in intestine and ASI neurons [35]), we infer that
metformin requires SKN-1 activities in both ASI neurons and
intestinal SKN-1 to increase healthspan. We note, however, that
this conclusion rests on the assumption that the tissue-specific
transgene expression we tested (functional in ref [35]) provides the
expression levels appropriate for rescuing SKN-1 functions in
these tissues.
How does metformin activate SKN-1? Metformin has been
shown to increase ROS production in mammalian cells [86]. In
C. elegans, DR has been associated with sensitivity to ROS
stressors ([87] and Fig. S4), low glucose levels have been shown to
promote ROS formation in [78], and LKB1/PAR-4 has been
shown to be the upstream kinase of AAK-2 in a pathway needed
for oxidative stress resistance [68], implicating ROS in pathways
relevant to the metformin model. We therefore speculate that
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where it functions to defend against oxidative stress and promote
longevity. Such a model is consistent with our observation that
metformin treatment is actually detrimental to the animals
expressing SKN-1 only in the ASI neurons and not in the
intestine (Fig. 4C)–intestinal SKN-1 may promote organism
healthspan by counteracting some of the effects of metformin-
induced SKN-1 signaling in ASI neurons.
SKN-1 is orthologous to the mammalian Nrf transcription
factors (Nrf1 and Nrf2) that activate genes encoding phase 2
detoxification enzymes [88,89]. Notably, Nrf2 defends against age-
related diseases such as neurodegeneration, chronic inflammation,
and cancer [90,91]. Our results highlight the potential of Nrf
transcription factors to play required roles in health-promoting
effects of metformin in mammals.
A Genetic Tool for Evaluating Healthspan Therapies
In humans, metformin increases survival rates in diabetic and
cardiovascular disease patients [1,2], but healthspan impact on
non-diseased individuals has not been established. In C. elegans,
metformin treatment extends median lifespan in normal wild type
animals as well as in mutants with disrupted insulin signaling
pathways, supporting potential application of metformin as a
prophylatic anti-aging strategy in healthy individuals. Because the
nematode model exhibits multiple commonalities associated with
metformin treatment in mammals, it appears that the basic
mechanism of metformin action involves conserved metabolic
relationships. We suggest that the C. elegans model is therefore well
suited to detailed elucidation of the physiological mechanism of
metformin action and may be particularly useful for screening for
chemically modified biguanides that have increased efficacy in
healthspan promotion but lack deleterious side effects associated
with metformin.
Overall, our results support that metformin acts through LKB1,
AMPK, and SKN-1 in a conserved biochemical mechanism to
engage DR metabolism and anti-oxidant defenses to extend
healthspan in C. elegans, a conclusion that holds significant
implications for development of anti-aging therapies.
Materials and Methods
C. elegans Cultures
The following strains used in this study were obtained from the
Caenorhabditis Genetics Center (CGC, University of Minnesota):
wild-type Bristol N2, TJ1052 age-1(hx546), CB1370 daf-2(e1370),
GR1307 daf-16(mgDf50), DA1116 eat-2(ad1116), RB754 aak-
2(ok524), MR507 aak-2(rr48), KK184 par-4(it47), KK300 par-
4(it57), CL2166 N2 dvIs19[pAF15(gst-4::GFP::NLS)] and EU31 skn-
1(zu135)/nT1[unc-?(n754) let-?]. LD001 N2 Is007[skn-1::gpf;rol-
6dm] was generated by J. H. An and T. K. Blackwell. The skn-1
strains used for mosaic analyses, LG333 skn-1(zu135);Is007[skn-
1::gfp;rol-6dm], LG348 skn-1(zu135)/nT1[qIs51];geIs9[gpa-4p::skn-
1b::gfp; rol-6(su1006)], and LG357 skn-1(zu135)/nT1[qIs51];
geIs10[ges-1p::skn-1c::gfp; rol-6(su1006)], were kindly provided by
L. Guarente and N. Bishop. All strains were grown and
maintained on NGM plates seeded with Escherichia coli OP50
[92]. All experiments were performed at 20uC except for lifespan
assays with daf-2(e1370), par-4(it47), and par-4(it57) (see below).
Metformin (Aldrich, Catalog # D15,095-9) was added directly to
the NGM agar media to a final concentration of 1, 10, 50, or
100 mM from a 1 M aqueous stock. Note that C. elegans is often
fairly resistant to drug uptake and doses in the worm are expected
to be much lower than plate concentrations.
Lifespan Assays
Lifespan analyses were performed in the same manner for all
strains, except for experiments with daf-2(e1370), par-4(it47),a n d
par-4(it57). daf-2(e1370) L2 larvae enter diapause at restrictive
temperatures [25,93] and thus daf-2(e1370) animals were main-
tained at 15uC and shifted to 20uC on the first day of adulthood
during lifespan assays. The par-4 strains are temperature-sensitive
maternal effect lethal [66,67], and were maintained at 15uCa n d
shifted to 25uC at the L4 stage for lifespan studies. The daf-2(e1370)
and par-4 animals were placed on metformin-containing plates on
the day of temperature shift. For each experiment, except where
otherwise noted, the lifespan of 60 animals was measured in each
trial. For each concentration of metformin tested, we placed 15 L4-
stage larvaeon3plateswith 5animalsperplateand allowedtheseto
develop to adulthood and then lay eggs over 24 hours. These
parental animals were then removed from the plates. 48 hours later,
60 (day 2) L4 larvae were transferred to fresh plates. These animals
were transferred to fresh plates every day during the progeny
production period, and then every other day thereafter. Animals
that did not move when gently prodded were scored as dead.
Animals that crawled off the plate or died from vulva bursting or
internal hatching were not included in lifespan counts.
Locomotion Assays
Animals were raised from eggs similar to the lifespan assays. On
days 5, 10, and 15 of life, 30 individuals from the control or
experimental plates were measured for body bend rate in liquid.
Briefly, 10 animals were placed in 20 ml M9 buffer on a glass slide
and filmed for 30 seconds using a Qimaging Rotera-XR digital
camera attached to a dissecting microscope and Streampix
imaging software (ver. 3.17.2, NorPix). Body bends were counted
by reviewing each frame of the 30 second film. Results are the
averages of three independent trials.
Age Pigment Fluorescence Spectroscopy
Age pigment fluorescence intensity was measured as described
[50]. Wild-type animals were raised from eggs on plates as in the
lifespan assays until day 5 of life. On day 5, 50 animals were
transferred to 50 ml 10 mM NaN3 solution in a single well of a 96-
well white FluoroNunc plate (Nalge Nunc Int’l). The animals were
scanned using an in vivo spectrofluorimeter (Fluorolog-3, Jobin
Yvon Inc., Edison NJ). Peak age pigment fluorescence intensity
was determined by scanning through a range of excitation
wavelengths from 280–410 nm and an emission wavelength of
430 nm. DataMax data acquisition software (v. 2.20, Jobin Yvon
Inc.) and Grams/32 data manipulation software (v. 4.14, Galactic
Industries Corp.) were used to process the emission data. Scores
are the average age pigment fluorescence intensity levels of three
independent trials.
Fecundity Assays
Wild-type animals were raised from eggs similar to the lifespan
assays. Animals were transferred to fresh plates every day during
the progeny production period, and the original plates were left at
20uC for 24 hours to allow viable eggs to hatch and were then
stored at 4uC to be scored at the end of the experiment. Data
shown represent the average of three independent trials.
Nile Red Staining and Fluorescence Spectroscopy
Wild-type L4 animals were placed on plates and allowed to
develop for 2 days. For lipid staining, these egg-laying parental
animals were transferred to plates layered with 120 mlo fa5 0 0mg/
mL Nile Red (Molecular Probes N-1142) [53,54] stock in acetone or
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lay eggs for several hours, then removed. 5 days later, progeny were
scanned for Nile Red fluorescence similar to as described for age
pigments. Nile Red fluorescence intensity was read at an emission
wavelength of 658 nm and an excitation wavelength of 578 nm [53].
Therewasnodetectablefluorescenceattheseexcitationandemission
wavelengths in worms raised on plates containing no Nile Red dye.
Data represent the average of three independent experiments.
Pharyngeal Pumping Assays
Wild-type animals were raised from eggs on plates similar to the
lifespan assays. On day 4 of life, the pharyngeal pumping rates of
10 individuals were measured by transferring single animals to
an unseeded plate and scoring pharyngeal pumping under a
dissecting microscope for 30 seconds. Data represent the averages
of three separate experiments.
Nuclear SKN-1::GFP Quantitation
N2 Is007[skn-1::gfp;rol-6dm] or aak-2(ok524);Is007[skn-1::gfp;rol-6dm]
animals were raised from eggs as in the lifespan assays. L4 animals
were placed in 10 mM NaN3 or M9 liquid media and observed
under a 40x objective lens using a Zeiss Axioplan 2 microscope
equipped with an X-cite Series 120 (EXPO Photonic Solution, Inc.)
fluorescence illuminator. Micrographs were obtained using an
Optronics digital microscope camera and Magnafire processing
software. 50 animals were observed for each experimental condition.
Statistical Analyses
Log-rank(Mantel-Cox)tests,Gehan-Breslow-Wilcoxontests,and
unpaired t tests were performed using GraphPad Prism version 5.00
for Windows (GraphPad Software, San Diego California).
Supporting Information
Figure S1 Metformin triggers the dietary restriction (DR)-
specific fluorescent profile. Age pigment fluorescence measure-
ments in wild-type animals raised on 0 mM and 100 mM met-
formin plates. As in Fig. 2B, we measured age pigment
fluorescence in five-day-old nematodes. In the trial presented
here, 100 mM metformin decreased age pigment fluorescence
levels as compared to the 0 mM control (86413 a.u. versus 148734
a.u., respectively; a.u.=arbitrary units). In addition, 100 mM
metformin induced a shift in the excitation wavelength corre-
sponding to the maximum age pigment fluorescence intensity
(ExMax shift, 331 nm for 100 mM metformin versus 339 nm for
the 0 mM control). Since 100 mM metformin did not extend mid-
life viability well (possibly due to starvation or excessive DR
signaling), we chose to work with lower doses of the drug.
Found at: doi:10.1371/journal.pone.0008758.s001 (0.07 MB TIF)
Figure S2 Metformin has detrimental effects on healthspan if
AMPK is mutant. A. Swimming rates for aak-2(ok524) and aak-
2(rr48)AMPK mutants raisedfrom eggs onplatescontaining0 mM
and 50 mM metformin at 20uC. Swimming was recorded on days 5
and 10 of life as in Fig. 1B. In both strains, 50 mM metformin
significantly decreases swimming rates on both day 5 and day 10 of
life (P=0.0002 and P,0.0001 for aak-2(ok524) on days 5 and 10,
respectively; P=0.0272 and P,0.0001 for aak-2(rr48) on days 5
and 10, respectively), indicating that metformin decreases locomo-
tory healthspan when AMPK signaling is disrupted. These data
represent the averages of three independent trials for each
experiment. B. Nile Red levels of aak-2(ok524) mutants raised on
0, 1, 10, and 50 mM metformin were measured on day 5 of life.
Data from three independent trials show that metformin had no
significant effect on the levels of Nile Red fluorescence at any of the
tested concentrations. C. Exposure to 50 mM metformin signifi-
cantly reduced levels of age pigments (P=0.0327). These results
indicate that functional AMPK is required for metformin to reduce
fat levels, but not age pigment accumulation, in Caenorhabditis elegans.
These observations suggest that metformin signals through different
pathways to influence healthspan.
Found at: doi:10.1371/journal.pone.0008758.s002 (0.10 MB TIF)
Figure S3 Metformin induces intestinal nuclear SKN-1::GFP
accumulation and the expression of SKN-1 target gene reporter,
pgst-4GFP::NLS. A. N2 Is7[skn-1::gfp;rol-6dm] animals were
raised from eggs on 0 mM or 50 mM plates to the L4 stage, and
then placed in liquid M9 media for quantification of intestinal
nuclear SKN-1::GFP accumulation. Animals exposed to 50 mM
metformin had significantly higher levels of nuclear SKN-1::GFP
accumulation versus controls (P,0.0001 by the Chi-square test).
90 animals were examined for the 0 mM metformin group and 93
animals were observed for the 50 mM metformin group. ‘‘Low’’
indicates very little or no SKN-1::GFP localization to intestinal
nuclei; ‘‘Medium’’ indicates strong SKN-1::GFP localization to
nuclei in the anterior and/or posterior of the intestine; ‘‘High’’
indicates strong SKN-1::GFP accumulation in nuclei throughout
the entire intestine. B. Animals expressing a transcriptional
fusion reporter of the SKN-1 target gst-4 (dvIs19[pAF15(gst-
4::GFP::NLS)]) [72] were raised on 0 and 50 mM metformin, and
GFP fluorescence intensity was measured on day 5 of life using a
spectrofluorimeter. Animals exposed to 50 mM metformin had
significantly higher GFP fluorescence levels versus controls
(P=0.0249), indicating the induction of gst-4 expression by
metformin. The results of two independent trials are shown here.
Found at: doi:10.1371/journal.pone.0008758.s003 (0.07 MB TIF)
Figure S4 Dietary restriction (DR)-constitutive eat-2(ad1116)
mutants are sensitive to oxidative stress. The survival rates of
wild-type N2, the mev-1(kn1) mitochondrial cytochrome b subunit
mutant, and the DR-constitutive eat-2(ad1116) mutants were
measured with exposure to 100 mM of the oxidative stressor
paraquat on day5 of life. Fifty animals perstrainwere used pertrial,
and the pooled results of two independent trials are shown here.
mev-1(kn1) mutants are sensitive to paraquat, and showed
significantly reduced survival rates when exposed to 100 mM
paraquat versus N2 (P,0.0001, Log-rank test). eat-2(ad1116)
mutants were even more sensitive to paraquat than mev-1(kn1)
animals, and showed significantly reduced survival rates on
100 mM paraquat as compared to both N2 and mev-1(kn1)
(P,0.0001 for both, Log-rank test).
Found at: doi:10.1371/journal.pone.0008758.s004 (0.06 MB TIF)
Table S1 Lifespan data for all metformin trials.
Found at: doi:10.1371/journal.pone.0008758.s005 (0.27 MB
DOC)
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